With an increasing understanding of the molecular mechanisms underlying lung cancer, the treatment approach for non-small cell lung cancer (NSCLC) has evolved to prioritize the identification of specific oncogenic driver mutation subtypes, especially epidermal growth factor receptor (EGFR) mutations, which are the most common gene mutations and indicate longer overall survival for patients with NSCLC [7, 8]. The gene discussed is EGFR; the disease is lung carcinoma.